This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BACKGROUND:In heart failure, sympathetic excess and exercise intolerance impair quality of life. In heart failure with reduced ejectionfraction, exercise stimulates a reflex increase in muscle sympathetic nerve activity (MSNA) that relates inversely to peak oxygen uptake (VO2peak).
BackgroundThe renal sympathetic nervous system modulates systemic bloodpressure, cardiac performance, and renal function. Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preservedejectionfraction (HFpEF).We
BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preservedejectionfraction (HFpEF); yet, specific underlying mechanisms remain unclear. We defined HFpEF based on the presence of elevated left ventricular filling pressures at rest or during exercise. P<0.001).
Intro:Drug Development for Heart failure with PreservedEjectionFraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups. HFD/L-NAME mice showed altered exercise capacity (p<0.05
ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with Heart Failure With PreservedEjectionFraction, (..)
25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preservedejectionfraction during the session;"Innovations and Insights in Heart Failure With PreservedEjectionFraction: Emerging Therapies, Biomarkers and Mechanistic Studies."
Muscle quality and cardiac function in heart failure with preservedejectionfraction (HFpEF) during exercise. Therefore, the study aimed to determine the relationship between locomotor MQ and cardiac function during exercise in HFpEF. MQ was calculated as peak watts divided by LL%. vs. 2.3 ± 0.6 W/%,
25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preservedejectionfraction during the session;"Innovations and Insights in Heart Failure With PreservedEjectionFraction: Emerging Therapies, Biomarkers and Mechanistic Studies."
The analysis sought to determine whether phenotypic features and treatment effects of semaglutide vary by sex in obesity-related heart failure ( HF ) with preservedejectionfraction (HFpEF). It also lowered their systolic bloodpressure and waist circumference.
Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S. The study was funded by Imbria Pharmaceuticals, developer of ninerafaxstat.
4] More recently, at least at the epidemiologic level, the obesity paradox has been confirmed in both heart failure with reduced ejectionfraction (HFrEF) and heart failure with preservedejectionfraction (HFpEF), but also in those with coronary heart disease. [5, Carbone, Salvatore, et al. Future Cardiology 13.5
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content